Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks

Area of Science:

• Cardiology
• Hematology
• Translational Research

Background:

• Platelet activation and reactivity are crucial in atherothrombotic events like acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI).
• Established thresholds for platelet reactivity during dual antiplatelet therapy correlate with increased ischemic event risk.
• The clinical utility of these thresholds for modifying P2Y12 receptor therapy is under investigation in large trials.

Purpose of the Study:

• To explore the association between on-treatment platelet reactivity and bleeding events.
• To evaluate the potential of preoperative platelet function monitoring in guiding coronary artery bypass grafting (CABG) timing and blood product administration.

Main Methods:

• Review of translational research studies and clinical trials.
• Analysis of ex vivo platelet reactivity assays.
• Assessment of evidence linking platelet inhibition to bleeding events.

Main Results:

• A higher risk of ischemic events is observed when platelet reactivity exceeds established thresholds during dual antiplatelet therapy.
• Limited evidence currently exists for a direct association between platelet inhibition and CABG-related bleeding in patients on clopidogrel.
• Preoperative platelet function monitoring shows potential for guiding surgical decisions.

Conclusions:

• While thresholds for platelet reactivity are linked to ischemic events, their clinical validity in modified P2Y12 therapy requires further large-scale trial validation.
• Routine platelet function monitoring and surgery timing adjustments are not currently recommended due to insufficient evidence from large prospective trials.